NeuroBo Pharmaceuticals, Inc.
https://www.neurobopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NeuroBo Pharmaceuticals, Inc.
Asia Deal Watch: Lotus Brings Corium’s Donepezil Patch To 10 Markets
Plus deals from Huadong/Arcutis, SK Bioscience/Novavax, NeuroBio/MThera, CASI/Mundipharma/Acrotech, Amarin/Lotus and Synergy/Livzon.
Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
Dong-A ST Faces New Wave Of Change As It Challenges Norms
Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.
How KIMCo Is Orchestrating Korean Pharma Collaborations
KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Gemphire Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice